ZLDPF OTC
Zealand Pharma A/S
1W: -4.7%
1M: -15.4%
3M: -12.3%
YTD: -44.6%
1Y: -47.9%
3Y: -4.8%
5Y: +43.6%
$40.00
+1.90 (+4.99%)
Weekly Expected Move ±8.2%
$33
$37
$40
$43
$47
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$9.2B
+14565.6% ▲
5Y CAGR: +91.9%
Gross Profit
$9.2B
+16620.8% ▲
5Y CAGR: +103.5%
Operating Income
$7.1B
+661.2% ▲
Net Income
$6.4B
+697.0% ▲
EPS (Diluted)
$90.04
+654.4% ▲
EBITDA
$7.2B
+800.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $293M | $104M | $343M | $63M | $9.2B |
| YoY Growth | -17.2% | -64.5% | +229.6% | -81.7% | +14565.6% |
| Cost of Revenue | $119M | $31M | $19M | $8M | $28M |
| Gross Profit | $174M | $73M | $324M | $55M | $9.2B |
| Gross Margin | 59.4% | 70.5% | 94.4% | 87.4% | 99.7% |
| R&D Expenses | $588M | $614M | $685M | $920M | $1.6B |
| SG&A Expenses | $636M | $307M | $90M | $229M | $273M |
| Operating Expenses | $1.2B | $921M | $896M | $1.3B | $2.0B |
| Operating Income | -$1.1B | -$817M | -$572M | -$1.3B | $7.1B |
| Operating Margin | -359.0% | -785.3% | -166.9% | -2029.3% | 77.7% |
| Interest Expense | $4M | $56M | $25M | $34M | $38M |
| Income Before Tax | -$764M | -$972M | -$709M | -$1.1B | $7.0B |
| Tax Expense | -$9M | -$6M | -$5M | -$5M | $545M |
| Net Income | -$1.0B | -$966M | -$704M | -$1.1B | $6.4B |
| Net Margin | -348.0% | -928.6% | -205.3% | -1720.9% | 70.0% |
| EPS (Diluted) | $-23.75 | $-20.90 | $-12.44 | $-16.24 | $90.04 |
| EBITDA | -$712M | -$665M | -$658M | -$1.0B | $7.2B |
| Shares Outstanding | 43M | 46M | 57M | 66M | 72M |